LENZ Therapeutics, Inc. Income Statement
LENZ / Health Care|6 years of annual SEC 10-K data (FY2020-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 6 fiscal years. All figures from audited SEC 10-K filings.
LENZ Therapeutics, Inc. reported $19M in revenue and $82M in net loss for FY2025. Its profit margin was -430.3% in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 4.71 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | $19.1M | - | - | - | - | - |
| Cost of Revenue | $418.0K | - | - | - | - | - |
| SG&A Expense | $91.1M | $28.8M | $12.9M | $32.9M | $22.5M | $4.4M |
| R&D Expense | $18.7M | $29.8M | $59.5M | $72.8M | $37.9M | $9.1M |
| Operating Income | -$91.1M | -$58.6M | -$72.4M | -$105.6M | -$60.4M | -$13.5M |
| Income Tax | $502.0K | $1.0K | -$179.0K | $0 | $0 | $0 |
| Net Income | -$82.1M | -$49.8M | -$70.0M | -$101.1M | -$70.8M | -$68.4M |
| EPS (Basic) | -$2.85 | -$2.34 | -$35.71 | -$1.84 | -$2.45 | - |
| EPS (Diluted) | -$2.85 | -$2.34 | -$35.71 | -$1.84 | -$2.45 | - |
| Shares Outstanding | 31.3M | 21.3M | 2.0M | 54.9M | 28.9M | 2.3M |
| Operating Margin | -477.5% | - | - | - | - | - |
| Profit Margin | -430.3% | - | - | - | - | - |